Neurocrine Biosciences (NBIX) Tops Q1 EPS by 13c; reaffirms guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $155.95 +0.20%
EPS Growth %: -12.4%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -12.4%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $1.20, $0.13 better than the analyst estimate of $1.07. Revenue for the quarter came in at $515.3 million versus the consensus estimate of $512.36 million.
GUIDANCE
INGREZZA Net Product Sales of $2,100- $2,200M
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- RBC Capital on Neurocrine Bio. (NBIX): 'We like the setup and remain buyers'
- ASP Isotopes holds first capital markets day, targets $300M EBITDA by 2031
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
